公开(公告)号：EP2352374A4

公开(公告)日：2012-03-28

申请号：EP09824011

申请日：2009-10-19

申请人： MERCK SHARP & DOHME ,  METABASIS THERAPEUTICS INC

发明人： DANG QUN ,  CHUNG DE MICHAEL ,  GIBSON TONY S ,  JIANG HONGJIAN ,  CASHION DANIEL K ,  BAO JIANMING ,  LAN PING ,  LU HUAGANG ,  MAKARA GERGELY M ,  ROMERO F ANTHONY ,  SEBHAT IYASSU ,  WODKA DARIUSZ

IPC分类号： C07D235/26 ,  A61K31/4184 ,  C07D235/28 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04

CPC分类号： C07D235/28 ,  C07D235/26 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04

公开(公告)号：EP2265605A1

公开(公告)日：2010-12-29

申请号：EP09722911.6

申请日：2009-03-18

申请人： Dr. Reddy's Laboratories, Ltd. ,  Dr. Reddy's Laboratories Ltd

发明人： KOLLA, Naveen, Kumar ,  MANNE, Nagaraju ,  GANGULA, Srinivas ,  NEELAM, Udaykumar ,  NAREDLA, Anitha ,  BADDAM, Sudhakar, Reddy ,  PATIL, Sumeet, Vishwasrao ,  TUMMALA, Arjunkumar ,  PEDDIREDDY, Subbareddy ,  SHINDE, Sachin, Gulabrao ,  SIGALA, Ashok ,  MUDUNURU, Satish Varma ,  TUMMIDI, Madhu, Kiran

IPC分类号： C07D403/12 ,  C07D235/28 ,  C07D235/24

CPC分类号： C07D401/12 ,  A61K9/1635 ,  A61K9/1652 ,  A61K47/6951 ,  B82Y5/00

摘要： Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.

公开(公告)号：EP2217577A4

公开(公告)日：2010-12-08

申请号：EP08853900

申请日：2008-11-26

申请人： ARDEA BIOSCIENCES INC

发明人： QUART BARRY D ,  GIRARDET JEAN-LUC ,  GUNIC ESMIR ,  YEH LI-TAIN

IPC分类号： C07D249/12 ,  C07D235/28

CPC分类号： A61K31/4196 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  C07D249/12 ,  C07D249/14 ,  C07H7/02 ,  C07H19/06 ,  C07H19/16

摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

公开(公告)号：EP1914225A4

公开(公告)日：2010-08-11

申请号：EP06731253

申请日：2006-04-06

申请人： KONICA MINOLTA HOLDINGS INC

发明人： KOKEGUCHI NORIYUKI

IPC分类号： C07C323/12 ,  C07C323/25 ,  C07C323/36 ,  C07C323/52 ,  C07D213/32 ,  C07D235/28 ,  C07D249/12 ,  C07D257/04 ,  C07D263/58 ,  C07D271/10 ,  C07D277/04 ,  C07D277/72 ,  C07D285/00 ,  C07D285/125 ,  C07D327/00 ,  C07D341/00 ,  G02F1/17

CPC分类号： C07D263/58 ,  C07C323/12 ,  C07C323/25 ,  C07C323/36 ,  C07C323/49 ,  C07C323/52 ,  C07C323/58 ,  C07C323/60 ,  C07C323/66 ,  C07C323/67 ,  C07C335/32 ,  C07D249/12 ,  C07F1/005 ,  G02F1/1506

公开(公告)号：EP1566381B1

公开(公告)日：2009-11-11

申请号：EP03775913.1

申请日：2003-11-27

申请人： Kowa Co., Ltd.

发明人： SHIBUYA, Kimiyuki ,  SATO, Yukihiro

IPC分类号： C07D235/28 ,  C07D295/18

CPC分类号： C07D235/28

摘要： A process of producing 1-[2-(benzimidazol-2-ylthio)- ethyl]piperazine (5) or salts thereof according to the reaction scheme (I): The process makes it possible to produce efficiently 1-[2-(benzimidazol-2-ylthio)ethyl]piperazine serving as an intermediate in the production of cyclic diamines useful as ACAT inhibitor, or salts thereof.

公开(公告)号：EP2024336A1

公开(公告)日：2009-02-18

申请号：EP07724830.0

申请日：2007-05-03

申请人： KARO BIO AB

发明人： GARCIA COLLAZO, Ana Maria ,  KOCH, Eva, Kristina ,  LÖFSTEDT, Anton, Joakim ,  CHENG, Aiping ,  GORDON, Sandra ,  HANSSON, Tomas, Fredrik

IPC分类号： C07D235/06 ,  C07D235/08 ,  C07D235/10 ,  C07D235/14 ,  C07D235/18 ,  C07D235/24 ,  C07D235/28 ,  C07D235/30 ,  C07D403/04 ,  C07D407/04 ,  C07D413/04 ,  A61K31/4184 ,  A61K31/422 ,  A61P5/14

CPC分类号： C07D235/08 ,  C07D235/06 ,  C07D235/10 ,  C07D235/14 ,  C07D235/18 ,  C07D235/24 ,  C07D235/28 ,  C07D235/30 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04

摘要： The invention provides the use of compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, for the manufacture of a medicament for the treatment or prophylaxis of a condition that may be treated with a thyroid receptor agonist or partial agonist wherein R1, R2, R3, R4, Y, W and R5 are as defined in the specification. The invention also provides compounds of formula (Ia) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, formula (Ia) wherein R1, R2, R3, R4, Y, W and R5 are as defined in the specification.

公开(公告)号：EP1914225A1

公开(公告)日：2008-04-23

申请号：EP06731253.8

申请日：2006-04-06

申请人： KONICA MINOLTA HOLDINGS, INC.

发明人： KOKEGUCHI, Noriyuki, Konica Minolta Tech. Cntr.

IPC分类号： C07C323/12 ,  C07C323/25 ,  C07C323/36 ,  C07C323/52 ,  C07D213/32 ,  C07D235/28 ,  C07D249/12 ,  C07D257/04 ,  C07D263/58 ,  C07D271/10 ,  C07D277/04 ,  C07D277/72 ,  C07D285/00 ,  C07D285/125 ,  C07D327/00 ,  C07D341/00 ,  G02F1/17

CPC分类号： C07D263/58 ,  C07C323/12 ,  C07C323/25 ,  C07C323/36 ,  C07C323/49 ,  C07C323/52 ,  C07C323/58 ,  C07C323/60 ,  C07C323/66 ,  C07C323/67 ,  C07C335/32 ,  C07D249/12 ,  C07F1/005 ,  G02F1/1506

摘要： A salt molten at room temperature that does not contain any organic solvent, excelling in stability; and a display device that is improved in the durability in high-temperature environment by virtue of the use thereof. There is provided a salt molten at room temperature characterized by being composed of a silver salt and any of compounds of the following general formula (I) or general formula (II).

摘要翻译： 盐在室温下熔融，不含任何有机溶剂，稳定性好; 以及借助其使用在高温环境中提高耐久性的显示装置。 提供在室温下熔融的盐，其特征在于由银盐和下列通式（I）或通式（II）的任何化合物组成。

公开(公告)号：EP1848696A1

公开(公告)日：2007-10-31

申请号：EP06718840.9

申请日：2006-01-19

申请人： Schering Corporation

发明人： ASLANIAN, Robert, G. ,  TOM, Wing, C. ,  ZHU, Xiaohong

IPC分类号： C07D233/84 ,  C07D235/26 ,  C07D235/28 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D491/10 ,  A61K31/4164 ,  A61P11/06 ,  A61P37/08 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496

CPC分类号： C07D491/10 ,  C07D233/84 ,  C07D235/26 ,  C07D235/28 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

摘要： Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: n is 2-5; R is R3-aryl, R3-heteroaryl, R3-cycloalkyl, R3-heterocycloalkyl, alkyl, haloalkyl, -OR4, -SR4 or -S(O)1-2R5; R1 and R2 are H or optionally substituted phenyl or optionally substituted ; and X is -O- or -S-; or R1 and R2, together with the carbon atoms to which they are attached form optionally substituted (a or b) ; and X is -O-, -S- or -NR7-; Z is (c, d, e, f, g or h) ; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula (I); also disclosed are methods of treating allergy, allergy-induced airway responses, congestion, obesity and metabolic syndrome using the compounds of formula (I), as well as combinations with other drugs useful for treating those diseases.

公开(公告)号：EP1824831A2

公开(公告)日：2007-08-29

申请号：EP05857114.2

申请日：2005-12-16

申请人： Takeda San Diego, Inc.

发明人： BRESSI, Jerom, C. ,  BROWN, Jason, W. ,  GANGLOFF, Anthony, R. ,  JENNINGS, Andrew, J. ,  KALDOR, Stephen, W. ,  SKENE, Robert, J. ,  STAFFORD, Jeffrey, A. ,  VU, Phong, H.

IPC分类号： C07D235/06 ,  C07D235/26 ,  C07D233/32 ,  C07D263/58 ,  C07D277/68 ,  C07D235/30 ,  C07D471/04 ,  C07D235/28 ,  C07D277/70 ,  C07D401/12 ,  C07D401/04 ,  C07D409/06 ,  C07D409/04 ,  C07D403/04 ,  C07D405/04

CPC分类号： C07D235/06 ,  C07D235/26 ,  C07D263/38 ,  C07D263/58 ,  C07D277/68 ,  C07D277/72 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

摘要： Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formula: wherein the variables are as defined herein.

公开(公告)号：EP1814866A2

公开(公告)日：2007-08-08

申请号：EP05825094.5

申请日：2005-11-21

申请人： Wyeth

发明人： GARRICK, Lloyd, M. ,  GREEN, Daniel, M. ,  JETTER, James, W. ,  KAO, Wenling ,  KEES, Kanneth, L. ,  PELLETIER, Jeffrey, C. ,  ROGERS, John, F., Jr.

IPC分类号： C07D235/28 ,  C07D401/12 ,  C07D409/12 ,  C07D407/12 ,  C07D403/12 ,  C07D413/12 ,  A61K31/4184 ,  A61P35/00

CPC分类号： C07D235/30 ,  C07D235/18 ,  C07D235/26 ,  C07D235/28 ,  C07D295/192 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12

摘要： The present invention relates to Gonadotropin Releasing Hormone ('GnRH') (also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

摘要翻译： 本发明涉及促性腺激素释放激素（'GnRH'）（也称为黄体生成素释放激素）受体拮抗剂。